Federal Health Officials Say AstraZeneca Vaccine Trial May Have Relied on ‘Outdated Information’
Last Updated
March 23, 2021, 10:19 a.m. ET12 minutes ago
Federal officials said that an independent panel of medical experts questioned the promising results announced by the company on Monday.
U.S. health officials question results from AstraZeneca’s vaccine trial, less than a day after they’re released.
AstraZeneca’s Covid-19 vaccine being administered in Milan on Monday.Credit...Alessandro Grassani for The New York Times
Federal health officials said Tuesday that the encouraging results that AstraZeneca announced about its Covid-19 vaccine
may have been based on outdated and incomplete information about the vaccine’s effectiveness, an extraordinary blow to the credibility of an already embattled vaccine.
In a
statement released after midnight, the National Institute of Allergy and Infectious Diseases said that an independent panel of medical experts that has been helping to oversee AstraZeneca’s U.S. trial had “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.”
The exact nature of the institute’s concerns — and the effect they might have on how effective the vaccine appears to be — was unclear. But it is highly unusual for such a dust-up about the integrity of a clinical trial, especially one as high-profile as this, to occur in public.